These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

968 related items for PubMed ID: 33015726

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G, Mikhailidis DP, Sahebkar A.
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [Abstract] [Full Text] [Related]

  • 3. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS.
    Curr Vasc Pharmacol; 2020 Dec; 18(2):172-181. PubMed ID: 30961499
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G.
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K.
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
    Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L.
    Int J Mol Sci; 2022 Mar 27; 23(7):. PubMed ID: 35409028
    [Abstract] [Full Text] [Related]

  • 10. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
    Zachou M, Flevari P, Nasiri-Ansari N, Varytimiadis C, Kalaitzakis E, Kassi E, Androutsakos T.
    Eur J Clin Pharmacol; 2024 Jan 27; 80(1):127-150. PubMed ID: 37938366
    [Abstract] [Full Text] [Related]

  • 11. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.
    Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON.
    Int J Mol Sci; 2020 Mar 11; 21(6):. PubMed ID: 32168769
    [Abstract] [Full Text] [Related]

  • 12. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
    Belfort-DeAguiar R, Lomonaco R, Cusi K.
    J Clin Endocrinol Metab; 2023 Jan 17; 108(2):483-495. PubMed ID: 36305273
    [Abstract] [Full Text] [Related]

  • 13. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
    Patel Chavez C, Cusi K, Kadiyala S.
    J Clin Endocrinol Metab; 2022 Jan 01; 107(1):29-38. PubMed ID: 34406410
    [Abstract] [Full Text] [Related]

  • 14. Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study.
    Chang KC, Kuo FC, Yang CY, Yang CT, Ou HT, Kuo S.
    Cardiovasc Diabetol; 2024 Oct 17; 23(1):367. PubMed ID: 39420429
    [Abstract] [Full Text] [Related]

  • 15. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.
    Sumida Y, Seko Y, Yoneda M, Japan Study Group of NAFLD (JSG-NAFLD).
    Hepatol Res; 2017 Mar 17; 47(4):266-280. PubMed ID: 28019064
    [Abstract] [Full Text] [Related]

  • 16. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.
    Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, Kumar S, Siddiqi TJ, Usman MS.
    Dig Liver Dis; 2021 Jan 17; 53(1):44-51. PubMed ID: 32912770
    [Abstract] [Full Text] [Related]

  • 17. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H, Zhu X, Xia M, Yan H, Chang X, Hu X, Pan B, Guo W, Li X, Gao X.
    Endocr Pract; 2020 Apr 17; 26(4):444-453. PubMed ID: 31968197
    [Abstract] [Full Text] [Related]

  • 18. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease.
    Raschi E, Mazzotti A, Poluzzi E, De Ponti F, Marchesini G.
    Expert Opin Pharmacother; 2018 Dec 17; 19(17):1903-1914. PubMed ID: 30299993
    [Abstract] [Full Text] [Related]

  • 19. Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.
    Ishikawa T, Terai N, Sato R, Jimbo R, Kobayashi Y, Sato T, Iwanaga A, Sano T, Yokoyama J, Honma T.
    Intern Med; 2024 Sep 15; 63(18):2491-2497. PubMed ID: 38346734
    [Abstract] [Full Text] [Related]

  • 20. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.
    Metabolism; 2017 Jun 15; 71():17-32. PubMed ID: 28521870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.